INTRODUCTION
IPF is defined as a specific form of chronic fibrotic interstitial pneumonia associated with the histopathological appearance of usual interstitial pneumonia. The median survival of patients with IPF is reported to be 3-4 yr from the onset of respiratory symptoms (2000) . Despite such a poor prognosis, the etiology of IPF remains unknown, and no effective therapeutic strategy has yet been established. The effects of current immunosuppressive therapy with corticosteroids and cytotoxic agents are limited, and the adverse effects cannot be ignored. Therefore, the establishment of an alternative therapeutic strategy is urgently needed.
Since the overall cytokine pattern in biopsies and alveolar macrophages from patients with IPF appears to be more Th2-type (i.e., IL-4, IL-5, and IL-13) than Th1-type (i.e., IL-12 and IFN-γ) (Wallace et al., 1995; Furuie et al., 1997) , a biased Th2 cytokine profile in the lungs is regarded as one of the causes of IPF and, thus, a therapeutic strategy to correct this bias seems to be a promising approach. To the best of our knowledge, INF-γ, a major Th1 cytokine, is the only agent used for IPF patients in clinical studies as a therapeutic strategy targeted inhibition of Th2 cytokines. The rationale for its use was also based on its properties as an inhibitor of fibroblast proliferation, collagen synthesis and deposition. A recent meta analysis study showed 
Experimental protocol
After BLM was intratracheally administered, the mice were randomly divided into two groups, namely, BLM + suplatast tosilate (ST) group and BLM + Distilled water (DW) group. The mice of the BLM + ST group were given suplatast tosilate (100 mg/kg/day) by oral gavage daily until sacrificed; the mice of BLM + DW group received an equivalent volume of water. The control group received an equivalent volume of water after administrated PBS intratracheally. Animals were sacrificed 7, 14, and 21 days after BLM administration. Each group had 8 mice at each time point. The control group (n = 8 mice) was sacrificed at 21 days after intratracheal instillation of PBS.
Bronchoalveolar lavage (BAL) and cell analysis
The mice were sacrificed with a lethal dose of pentobarbital, the trachea was cannulated with an 18-gauge needle, and the lungs were lavaged twice with 1 ml of PBS.
The lavage fluids were pooled and were centrifuged at 300 g for 10 min at 4°C. The supernatants were stored at -80°C for the measurement of cytokine concentrations. The cell pellets were resuspended in 1 ml of Dulbecco's modified Eagle's medium, and the
To assess lung fibrosis biochemically, lung tissues were homogenized and then analysed for hydroxyproline content after acid hydrolysis, as described previously (Woessner, 1961) . Briefly, lung tissues were hydrolysed with 12N hydrochloric acid at 110°C for 24 hr. After neutralization with sodium hydroxide, the hydrolysates were diluted with distilled water. Hydroxyproline in the hydrolysates was assessed colourmetrically at 550 nm for p -dimethylaminobenzaldehyde. The results were expressed as micrograms of hydroxyproline contained in total lung tissue.
Preparation of AMs
AMs were isolated as previously described with slight modifications (Kaltreider et al., 1988) . Briefly, the mice were sacrificed with a lethal dose of pentobarbital and the trachea was cannulated with an 18-gauge needle. The lungs were lavaged 5 times with 1 ml of PBS containing 0.1% EDTA. The lavage fluids were pooled and centrifuged at 300 g for 10 min at 4°C. 
Assessment of MCP-1 production in AMs
First, the cells adhering to the plastic were isolated from the mice intratracheally instilled with BLM 7 days before and, then, incubated in the presence or absence of suplatast tosilate at concentrations of 10 and 100 µg/ml. Twenty four hours after the start of incubation with suplatast tosilate, the culture supernatants were collected and subjected for MCP-1 measurement. Next, the cells adhering to the plastic were isolated from normal mice. Following preincubation with or without suplatast tosilate for 3 hr, these cells were then incubated with LPS at the concentration of 1 µg/ml in the presence or the absence of suplatast tosilate. Twenty four hr after the addition of LPS, the culture supernatants were collected and MCP-1 concentration was measured.
Statistics
The results are expressed as the mean ± SEM. Differences between treatment groups were analyzed using ANOVA with Fisher's PLSD test for pairwise comparisons 
RESULTS

Effect of suplatast tosilate on BLM-induced pulmonary fibrosis
To determine whether suplatast tosilate has an anti-fibrotic effect on the development of pulmonary fibrosis, mice were treated with suplatast tosilate after BLM was intratracheally instilled. Fourteen and 21 days after BLM administration, the lungs were excised and collagen accumulation in the lungs was evaluated by measuring hydroxyproline content in the lungs. As shown in Fig A most interesting finding of the current study is that the treatment of BLM-injured mice with suplatast tosilate was found to effectively suppress the increased MCP-1 levels in BAL fluids. In addition, suplatast tosilate also was able to reduce the production of MCP-1 in AMs. Although MCP-1, which is produced by various types of This article has not been copyedited and formatted. The final version may differ from this version. and the development of pulmonary fibrosis (Zhang et al., 1994) . The MCP-1 levels in the sera and BAL fluids from IPF patients were also shown to be significantly higher than those in healthy subjects (Car et al., 1994; Suga et al., 1999) . MCP-1 mRNA and protein are strongly expressed in epithelial cells, macrophages, and endothelial cells in the lungs of IPF patients (Antoniades et al., 1992; Iyonaga et al., 1994) . In of MCP-1 expression in the lung. The expression of MCP-1 has been shown to be elevated on day 3 after BLM administration while it persisted until day 21 (Zhang et al., 1994) . In the present study, the MCP-1 levels in BAL fluid on day 7 after BLM administration dramatically increased and were still found to be significantly elevated on day 21 in the BLM-injured mice. Considering the expression pattern of MCP-1 in an animal model of BLM-induced pulmonary fibrosis, we believe that the treatment of the BLM-injured mice with suplatast tosilate, which started on the next day that BLM administration was begun and then continued daily until scarified, was necessary to elucidate the antifibrotic effect of suplatast tosilate mediated by the suppression of MCP-1.
In addition to MCP-1, the treatment of BLM-injured mice with suplatast tosilate significantly reduced the concentration of IL-6 in the BAL fluid 7 days after BLM administration. IL-6 is released by a variety of cells, including fibroblasts, and it has also been shown to mediate many inflammatory processes in the lung (Taga, 1997) . In animal models, the lung-specific overexpression of IL-6 has been shown to produce lymphocytic alveolitis but little fibrosis (Denis, 1992; DiCosmo et al., 1994; Yoshida et al., 1995) . Although in vitro studies have demonstrated the involvement of IL-6 in fibroblast proliferation, its role in fibrosis is still largely unknown (Knight et al., 2003) . Following the intratracheal instillation of bleomycin (1.5 mg/kg), suplatast tosilate (100 mg/kg/day) or distilled water was administered daily to mice by oral gavage. BAL fluid specimens were obtained 7, 14, and 21 days after the bleomycin administration, and total cell counts and differential cell counts were performed. Data are shown as the mean ±SEM for 8 mice per group at each time point. (*p<0.05 versus control group; †p<0.05 versus BLM + DW group).
BLM: bleomycin, DW: distilled water, ST: suplatast tosilate. 
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